U.S. Biotech Industry Analysis
UpdatedJun 25, 2024
DataAggregated Company Financials
Companies565
- 7D2.1%
- 3M-0.3%
- 1Y12.0%
- YTD3.5%
In the last week, the Biotech industry is up 2.1%, with Alnylam Pharmaceuticals leading the way with a 42% gain. In the same time, BridgeBio Pharma was down 16%. In the last 12 months, the industry was up 12%. As for the next few years, earnings are expected to grow by 25% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 25 Jun 2024 | US$1.2t | US$164.4b | -US$27,944,795,069.74 | 28.1x | -41.4x | 7x |
| Thu, 23 May 2024 | US$1.1t | US$164.6b | -US$26,731,616,038.85 | 24.6x | -42.6x | 6.9x |
| Sat, 20 Apr 2024 | US$1.1t | US$164.2b | -US$23,337,120,518.73 | 20.4x | -45.9x | 6.5x |
| Mon, 18 Mar 2024 | US$1.2t | US$167.4b | -US$22,071,849,383.64 | 13.9x | -53.2x | 7x |
| Wed, 14 Feb 2024 | US$1.1t | US$168.9b | -US$20,817,013,760.70 | 18x | -54.6x | 6.7x |
| Fri, 12 Jan 2024 | US$1.4t | US$204.8b | -US$22,495,274,678.00 | 19.2x | -64.1x | 7x |
| Sun, 10 Dec 2023 | US$1.3t | US$204.6b | -US$22,091,414,218.00 | 18.7x | -58.3x | 6.3x |
| Tue, 07 Nov 2023 | US$1.2t | US$203.9b | -US$22,185,418,652.00 | 18.9x | -56x | 6.1x |
| Thu, 05 Oct 2023 | US$1.2t | US$207.3b | -US$13,076,809,948.00 | 16.7x | -94.9x | 6x |
| Sat, 02 Sep 2023 | US$1.3t | US$207.6b | -US$12,424,624,459.00 | 18.4x | -104.2x | 6.2x |
| Mon, 31 Jul 2023 | US$1.2t | US$186.0b | -US$15,168,211,533.00 | 14.7x | -76.1x | 6.2x |
| Wed, 28 Jun 2023 | US$1.1t | US$186.3b | -US$16,125,527,732.00 | 13.5x | -69.1x | 6x |
| Fri, 26 May 2023 | US$1.1t | US$185.9b | -US$15,950,003,280.00 | 11.5x | -71.8x | 6.2x |
| Sun, 23 Apr 2023 | US$1.2t | US$198.4b | -US$3,214,788,122.00 | 13.9x | -370.1x | 6x |
| Tue, 21 Mar 2023 | US$1.1t | US$199.3b | -US$3,748,498,766.00 | 12.7x | -301.2x | 5.7x |
| Thu, 16 Feb 2023 | US$1.2t | US$202.5b | US$17.8m | 16.3x | 64811.8x | 5.7x |
| Sat, 14 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 670.8x | 5.8x |
| Mon, 12 Dec 2022 | US$1.1t | US$202.7b | US$1.4b | 14.6x | 811.7x | 5.6x |
| Wed, 09 Nov 2022 | US$1.1t | US$204.5b | US$3.9b | 14.4x | 280.2x | 5.3x |
| Fri, 07 Oct 2022 | US$1.1t | US$206.2b | US$5.5b | 15.1x | 193.6x | 5.1x |
| Sun, 04 Sep 2022 | US$1.0t | US$206.4b | US$6.2b | 14.6x | 167.9x | 5x |
| Tue, 02 Aug 2022 | US$1.0t | US$212.2b | US$11.4b | 15.4x | 90.7x | 4.9x |
| Thu, 30 Jun 2022 | US$1.0t | US$212.2b | US$11.0b | 15.7x | 94.5x | 4.9x |
| Sat, 28 May 2022 | US$1.0t | US$212.7b | US$11.1b | 16.1x | 92.8x | 4.8x |
| Mon, 25 Apr 2022 | US$1.2t | US$226.6b | US$14.7b | 17.8x | 81.5x | 5.3x |
| Wed, 23 Mar 2022 | US$1.3t | US$221.9b | US$10.6b | 19.8x | 122.3x | 5.9x |
| Fri, 18 Feb 2022 | US$1.2t | US$216.4b | US$5.7b | 21.9x | 214.8x | 5.7x |
| Sun, 16 Jan 2022 | US$1.3t | US$212.1b | US$2.5b | 24.4x | 527.3x | 6.2x |
| Tue, 14 Dec 2021 | US$1.4t | US$211.9b | US$3.1b | 25.2x | 449.8x | 6.7x |
| Thu, 11 Nov 2021 | US$1.5t | US$204.8b | -US$58,717,099.00 | 25.4x | -24760.2x | 7.1x |
| Sat, 09 Oct 2021 | US$1.5t | US$196.3b | -US$2,607,286,814.00 | 23.3x | -558.7x | 7.4x |
| Mon, 06 Sep 2021 | US$1.6t | US$196.4b | -US$2,275,254,373.56 | 22.4x | -705.5x | 8.2x |
| Wed, 04 Aug 2021 | US$1.6t | US$197.0b | -US$1,413,253,338.58 | 22.6x | -1110.5x | 8x |
Price to Earnings Ratio
-1810.8x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.8% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.48% | |
| Healthcare | 1.06% | |
| Biotech | 2.05% | |
| Biotech | 2.05% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | US$240.15 | 56.1% +US$10.9b | 27.2% | PS15.2x | |
| GILD Gilead Sciences | US$69.61 | 10.2% +US$8.0b | -8.4% | PE178.8x | |
| AMGN Amgen | US$319.31 | 4.4% +US$7.1b | 43.4% | PE45.5x | |
| SRPT Sarepta Therapeutics | US$158.06 | 34.5% +US$3.8b | 48.6% | PE884.2x | |
| REGN Regeneron Pharmaceuticals | US$1.07k | 3.1% +US$3.5b | 49.6% | PE30x |
